Drug intelligence / Profile preview

CD20-TXP1

Development stage: Preclinical
Lead developer: Ossianix
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

CD20-TXP1 is a blood-brain barrier (BBB)-penetrant therapeutic candidate being developed by Ossianix for the treatment of progressive multiple sclerosis (MS) and potentially cerebral lymphoma. It consists of a Type II anti-CD20 antibody genetically fused to TXP1, a second-generation, brain-selective single-domain VNAR antibody shuttle derived from sharks that targets transferrin receptor-1 (TfR1). This fusion enables receptor-mediated transcytosis across the BBB, resulting in a significant increase in central nervous system (CNS) exposure. Once in the CNS, CD20-TXP1 drives direct cellular cytotoxicity (DCC)-mediated B-cell depletion independent of complement, antibody-dependent cellular cytotoxicity (ADCC), or antibody-dependent cellular phagocytosis (ADCP).

Other names: CNS-targeted anti-CD20 antibodybrain-penetrant anti-CD20 antibody

Targets

CD20 (B-lymphocyte antigen CD20)TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on CD20-TXP1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD20-TXP1.